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Vg9Vd2 T cells respond in a TCR-dependent
fashion to both microbial and host-derived
pyrophosphate compounds (phosphoantigens, or
P-Ag). Butyrophilin-3A1 (BTN3A1), a protein struc-
turally related to the B7 family of costimulatory
molecules, is necessary but insufficient for this
process. We performed radiation hybrid screens
to uncover direct TCR ligands and cofactors
that potentiate BTN3A1’s P-Ag sensing function.
These experiments identified butyrophilin-2A1
(BTN2A1) as essential to Vg9Vd2 T cell recognition.
BTN2A1 synergised with BTN3A1 in sensitizing
P-Ag-exposed cells for Vg9Vd2 TCR-mediated re-
sponses. Surface plasmon resonance experiments
established Vg9Vd2 TCRs used germline-encoded
Vg9 regions to directly bind the BTN2A1 CFG-IgV
domain surface. Notably, somatically recombined
CDR3 loops implicated in P-Ag recognition were
uninvolved. Immunoprecipitations demonstrated
close cell-surface BTN2A1-BTN3A1 association in-
dependent of P-Ag stimulation. Thus, BTN2A1 is a
BTN3A1-linked co-factor critical to Vg9Vd2 TCR
recognition. Furthermore, these results suggest a
composite-ligand model of P-Ag sensing wherein
the Vg9Vd2 TCR directly interacts with both
BTN2A1 and an additional ligand recognized in a
CDR3-dependent manner.Immunity 52, 487–498, M
This is an open access article undINTRODUCTION
Human peripheral blood gd T cells are dominated from an early
age by Vg9Vd2 lymphocytes (Parker et al., 1990), an innate-like
subset that features a predominant effector status, allowing
potent cytokine production and cytotoxic capability that is linked
to a relatively restricted T cell receptor (TCR) repertoire (Davo-
deau et al., 1993; Delfau et al., 1992). Vg9Vd2 T cells universally
respond in a TCR-dependent fashion to non-peptidic pyrophos-
phate compounds (phosphoantigens [P-Ag]). These include the
microbially derived compound (E)-4-hydroxy-3-methyl-but-
2-enyl pyrophosphate (HMBPP) (Morita et al., 2007), which is
generated by the non-mevalonate isoprenoid synthetic pathway
and is a highly potent activator of Vg9Vd2 T cells. In addition,
host-cell-derived isoprenyl pyrophosphate (IPP) can act as a
P-Ag and stimulate Vg9Vd2 T cell responses. IPP levels are
elevated in some cancer cells and can also be therapeutically
increased in target cells via aminobisphosphonate drugs that
inhibit IPP catabolism, such as Zoledronate (Zol) (Gober et al.,
2003; Kunzmann et al., 2000).
Vg9Vd2-mediated P-Ag sensing requires cell-cell contact
(Morita et al., 1995) and depends on both Vg and Vd chains,
with evidence for involvement of multiple complementarity-
determining region (CDR) loops (Wang et al., 2010). An essential
prerequisite for P-Ag sensing is target-cell expression of butyro-
philin (BTN) 3A1 (Harly et al., 2012), a member of a multi-gene
family encoded on chromosome (Chr) 6. BTNs and butyrophi-
lin-like (BTNL) molecules are structurally related to the B7 family
of costimulatory molecules, comprising two extracellular immu-
noglobulin (Ig)-like domains, a transmembrane region, and a
cytoplasmic tail that often contains a B30.2 domain (Rhodesarch 17, 2020 ª 2020 The Authors. Published by Elsevier Inc. 487
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
et al., 2016). In addition to immunomodulatory effects on anti-
gen-presenting cells and conventional ab T cells, several BTN
and/or BTNL family members are emerging as playing critical
roles in gd T cell development and activation (Boyden et al.,
2008; Di Marco Barros et al., 2016; Harly et al., 2012; Melandri
et al., 2018; Vantourout et al., 2018; Willcox et al., 2019).
Although the extracellular domain of BTN3A1 was initially re-
ported to present P-Ag and directly bind the Vg9Vd2 TCR (Va-
vassori et al., 2013), other studies have challenged both of these
findings and instead support the concept that BTN3A1 senses
P-Ag directly. These data include robust evidence for P-Ag bind-
ing to the intracellular B30.2 domain of BTN3A1 and for a P-Ag-
induced conformational change (Nguyen et al., 2017; Salim et al.,
2017; Sandstrom et al., 2014). In addition, the importance of
BTN3A2 and/or BTN3A3 co-expression alongside BTN3A1 for
optimal P-Ag sensing has been highlighted, as well as the poten-
tial of these familymembers to heterodimerizewith BTN3A1 in an
IgC-dependent manner (Vantourout et al., 2018).
Vg9Vd2 T cells emerged with the appearance of placental
mammals and have been retained in both primates and species
as diverse as dolphin (Tursiops truncatus) and alpaca (Vicugna
pacos) (Fichtner et al., 2018; Karunakaran et al., 2014). Of
note, the alpaca is the only non-primate species to date with
proven P-Ag reactivity of Vg9Vd2 T cells and P-Ag binding to
BTN3 demonstrated (Fichtner et al., 2020). In contrast, rodents
lack BTN3, Vd2, and Vg9 homologs (Karunakaran et al., 2014).
Consistent with an important role in host immunity, Vg9Vd2
T cell expansion and activation is observed in a variety of micro-
bial infections (Morita et al., 2007). Furthermore, attempts to
therapeutically harness the human gd T cell compartment have
hitherto focused predominantly on the Vg9Vd2 subset in the
context of both specific infections (Shen et al., 2019) and cancer
(Kunzmann et al., 2000; Silva-Santos et al., 2019). From this
perspective, the mechanism underpinning Vg9Vd2 T cell activa-
tion has been a focus of strong interest.
Our previous studies have established that BTN3A1 is neces-
sary but not sufficient for P-Ag sensing and indicated the exis-
tence of an additional putative Chr-6-encoded factor that syner-
gized with BTN3A1 to stimulate P-Ag-mediated responses
(Rian˜o et al., 2014), which we subsequently coined ‘‘Factor X’’
(Karunakaran and Herrmann, 2014). Here, we set out to identify
Factor X using a radiation hybrid approach. We identified
BTN2A1 as this critical factor and showed it interacts directly
with the Vg9Vd2 TCR to potentiate P-Ag-dependent recognition,
highlighting its role in a ‘‘composite ligand’’ model of Vg9Vd2
T cell recognition.
RESULTS
Radiation Hybrids Identify BTN2A1 as Essential for P-Ag
Sensing
We showed previously that a T cell hybridoma expressing
the Vg9Vd2 MOP TCR produced interleukin (IL)-2 in co-culture
with BTN3A1-transduced Chinese hamster ovary (CHO) cells
incubated with the anti-BTN3A1 monoclonal antibody (mAb)
20.1 but exhibited a complete lack of response to HMBPP or
Zol (Rian˜o et al., 2014; Starick et al., 2017). In contrast, HMBPP
and Zol sensitivity was restored in co-cultureswith human-rodent
hybrid cells, including CHO cells containing a single human Chr 6488 Immunity 52, 487–498, March 17, 2020(CHO Chr6 cells). Based on this observation, we postulated the
existence of a Factor X encoded on Chr 6, which in addition to
BTN3A1 is mandatory for P-Ag-mediated gd T cell stimulation
(Rian˜o et al., 2014).
To identify Factor X, we used an unbiased genome-based
approach involving generation of radiation hybrids between
CHO-Chr 6 cells and BTN3A1-transduced hypoxanthine-
aminopterin-thymidine (HAT)-sensitive rodent fusion partners
and subsequent analysis of their capacity to stimulate P-Ag
sensing by Vg9Vd2 T cells (Figure 1A). We postulated that com-
parison of the human gene products transcribed in stimulatory
radiation hybrids would allow mapping of the gene(s), which
alongside BTN3A1 are mandatory for PAg-mediated stimulation.
We fused CHO-Chr6 cells separately with two HAT-sensitive
fusion partners—first BTN3A1-transduced A23 hamster cells
and second BTN3A1-transduced mouse BW cells (STAR
Methods) (Sanderson and Shastri, 1994); resulting radiation hy-
brids were assessed for P-Ag-dependent activation of TCR-
MOP transductants and positive candidates cloned by limiting
dilution. In some cases, these clones were used as donor cells
for further fusions. A final selection of clones (Figure S1A) were
subjected to RNA sequencing (RNA-seq) analysis (Figure 1B;
STAR Methods) alongside CHO-Chr6 cells and rodent fusion
partner cells as positive and negative controls, respectively.
A region of 580 kB of Chr 6 permitting P-Ag-mediated stim-
ulation by the radiation hybrids was identified (Figures 1C and
S1B). Analysis of candidate genes within this region revealed
that the only transmembrane molecules among the expressed
human genes were the major histocompatibility complex
(MHC)-class-I-like iron transporter HFE, the BTN3A1 gene
already transduced into rodent fusion partners, BTN3A2,
BTN3A3, andBTN2A1 andBTN2A2. Since we knew that expres-
sion of all three BTN3 genes was insufficient for reconstitution of
the P-Ag response (D.P., A.S.F., M.M.K., and T.H., unpublished
data),BTN2A1 andBTN2A2, which to date have been discussed
mainly for their immunomodulatory properties (Rhodes et al.,
2016), emerged as the prime candidates for encoding Factor X.
We then tested the effects on P-Ag-dependent stimulation of
Vg9Vd2 lymphocytes by human 293T cells after CRISPR-Cas9-
mediated inactivation of either both BTN2 genes (BTN2/) or
BTN2A1 (BTN2A1/) or BTN2A2 alone (BTN2A2/). Inactiva-
tion of both BTN2 genes completely abolished interferon (IFN)g
production by polyclonal Vg9Vd2 T cell lines in response to
Zol pulsed cells (Figure 1D). Crucially, both BTN2/ and
BTN2A1/ exhibited a complete loss of IL-2 production by
TCR-MOP cells in response to either HMBPP (Figure 1E) or
20.1 mAb (Figure 1F), whereas responses to BTN2A2/ were
similar to wild-type (WT) 293T cells (Figures 1E and 1F). These
experiments strongly suggested that alongside BTN3A1,
BTN2A1 was critical for P-Ag sensing.
BTN2A1 and BTN3A1 Are Sufficient to Potentiate
Vg9Vd2-Mediated P-Ag Sensing
To address whether BTN2A1 was sufficient alongside BTN3A1
to reconstitute P-Ag sensitization in rodent cells, we transduced
either one or both genes into both CD80+ BW and CD80+ CHO
cells (Figures 2A–2C) and tested their ability to induce IL-2 pro-
duction from TCR-MOP cells following incubation with HMBPP.
In both cases, whereas transduction of BTN3A1 alone resulted in
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Figure 1. Identification of BTN2A1 as Factor X
(A) Radiation hybrid approach to generate and identify rodent cell-fusion hybrids incorporating portions of human chromosome (Chr) 6 that permit P-Ag
sensitization.
(B) RNA-seq analysis of prioritized clones generated from fusion with A23 or BW cells. Values for less than three transcripts are merged with the x axis.
(C) Arrangement of BTN gene cluster on Chr 6 extracted from genome data viewer GRCh38.p13 (GCF_000001405.39).
(D) Production of IFNg from polyclonal Vg9Vd2 T cell lines in response to Zol-treated WT or BTN2/ 293T cells. Error bars represent standard deviation for three
independent experiments. **p < 0.005.
(E) Production of IL-2 from TCR-MOP transductants in response to HMBPP-treated WT, BTN2/, BTN2A1/, and BTN2A2/ 293T cells.
(F) Production of IL-2 from TCR-MOP transductants in response to 20.1 mAb-treated WT, BTN2/, BTN2A1/, and BTN2A2/ 293T cells.
In (E) and (F), the different colors indicate results from two independent experiments. See also Figure S1.negligible responses, transduction of both BTN2A1 and BTN3A1
permitted a robust, HMBPP-dose-dependent IL-2 response,
confirming their sufficiency for P-Ag sensitization (Figures 2B
and 2C). Interestingly, transduction of BTN2A1 alone resulted
in a weak, HMBPP-dose-independent basal response to both
cell lines (Figures 2B and 2C).
To assess whether BTN2A1 surface expression was able to
support binding to the Vg9Vd2 TCR, we generated Vg9Vd2
TCR tetramers and used them to stain transduced BW and
293T cells (Figures 2D and 2E). BTN2A1 expression on trans-
duced BW and 293T cells was sufficient to enable staining by
Vg9Vd2 MOP-TCR tetramer (Figures 2D, 2E, and S2A), support-
ing the idea that BTN2A1 may be a direct TCR ligand; moreover,
all Vg9Vd2 TCR tetramers tested stained BTN2A1-transduced
cells (Figure 2E). Consistent with the minimal basal BTN2A1-dependent IL-2 response observed in the absence of P-Ag or
BTN3A1 (Figures 2A and 2B), BTN3A1 co-expression was not
required for BTN2A1-mediated tetramer staining (Figure 2D),
nor was exposure to Zol necessary for tetramer staining (Fig-
ure 2F). This suggested BTN2A1might be an independent ligand
for the Vg9Vd2 TCR, the activatory potential of which is critically
augmented in a BTN3A1- and P-Ag-dependent manner.
We then investigated why BTN2A2, which shares close 88%
sequence identity with BTN2A1 in its extracellular region, was un-
able to potentiate P-Ag sensing alongside BTN3A1. BTN2A2-
293T transductants did not support tetramer staining (FigureS2A),
suggesting BTN2A2 might not be able to recognize the Vg9Vd2
TCR. However, one major caveat was the considerably lower sur-
face expression of BTN2A2 relative to BTN2A1 in 293T transduc-
tants (Figure S2B), which could also explain this observation.Immunity 52, 487–498, March 17, 2020 489
0 1 2 3 4
BTN2A1
BTN3A1
2° only
Streptavidin-PE alone
MOP TCR Tetramer-PE
anti-mouse 2° PE
anti-BTN2A1 + anti-mouse 2° PE
Untransduced
BTN2A1
BTN3A1
BTN2A1 + BTN3A1
G115 TCR
MOP TCR
D1C55 TCR
LES TCR
10 1 0.1
0
0
2
4
20
40
60
80
100
HMBPP (μM)
pe
rc
en
t a
ct
iv
at
io
n
10 3.3 1.1 0.3
7
0.1
2
0.0
4
0.0
1 0
0
20
40
60
80
100
HMBPP (μM)
pe
rc
en
t a
ct
iv
at
io
n
anti-mouse 2° PE
PE
TCR tetramer-PETCR tetramer-PE
Untransduced BTN3A1 BTN2A1 BTN2A1 + BTN3A1
BW 293T BTN2-/- 293T BTN2-/- + BTN2A1
Untransduced
- Zol
Untransduced
+ Zol
BTN2A1 + BTN3A1
- Zol
BTN2A1 + BTN3A1
+ Zol
A B
C D E
F
BW
BW BTN2A1
BW BTN3A1
BW BTN2A1 
+ BTN3A1
CHO
CHO BTN2A1
CHO BTN3A1
CHO BTN2A1 
+ BTN3A1
Figure 2. BTN2A1 and BTN3A1 Synergize to Potentiate P-Ag Sensing in Rodent Cells
(A) Expression of BTN2A1, BTN3A1, or both genes in transduced BW cells.
(B) Production of IL-2 by TCR-MOP transductants in response to HMBPP-treated CD80+ BW cells transduced to express BTN2A1, BTN3A1, both, or un-
transduced controls. Percentage activation is normalized against the maximum response obtained fromCD80+ CHO cells expressing both BTN2A1 and BTN3A1
in the presence of 10 mM HMBPP.
(C) Production of IL-2 from TCR-MOP transductants in response to HMBPP-treated CD80+ CHO cells transduced with either BTN2A1, BTN3A1, both genes, or
untransduced controls, with responses normalized as in (B).
Error bars in (B) and (C) represent standard deviation for three independent experiments. Differences between untransduced and BTN2-transduced cells were
significant (p < 0.05), as were those between the BTN2A1-transductant and BTN2A1+BTN3A1-transductant in the presence of HMBPP.
(D) MOP-TCR tetramer staining of transduced BW cells.
(E) Staining of transduced 293T cells with Vg9Vd2 TCRs.
(F) MOP-TCR tetramer staining or anti-BTN2A1mAb staining of BTN2A1 and BTN3A1-transduced CD80+ BW cells versus untransduced controls in the presence
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See also Figure S2.BTN2A1 IgV Domain Directly Binds Germline-Encoded
Regions of Vg9+ TCRs
To establish whether BTN2A1 acted as a direct ligand for the
Vg9Vd2 TCR, we expressed the membrane-distal domain of
the BTN2A1 ectodomain and tested direct binding to recombi-
nant Vg9Vd2 TCR using surface plasmon resonance (SPR). In-
jection of BTN2A1 IgV produced substantially enhanced signals
over surfaces with immobilized Vg9Vd2 TCR relative to Vg4Vd5
and Vg2Vd1 TCRs or control streptavidin surfaces, indicating
specific binding (Figure 3A). Equilibrium affinity measurements
of BTN2A1 IgV binding to the G115 and MOP Vg9Vd2 TCRs es-
tablished Kd values of 45.4 mM (n = 9) and 49.9 mM (n = 8), respec-
tively (Figure 3B).
Unexpectedly, experiments also indicated clear binding of
BTN2A1 IgV to a Vg9Vd1 TCR, which was derived from the
non-P-Ag reactive Vd1+ T cell subset (Halary et al., 2005) (Fig-490 Immunity 52, 487–498, March 17, 2020ure 3A); consistent with this, Vg9Vd1 TCR tetramers specifically
stained BTN2A1-transduced 293T cells (Figure S3A). Taking
into account the highly similar affinity (Kd 46.6mM [n = 8]) of the
BTN2A1-Vg9Vd1 TCR interaction (Figure 3B) and the radically
divergent CDR3g expressed by this TCR relative to Vg9Vd2
TCRs (Figure S3A), these results strongly suggested the
BTN2A1-Vg9Vd2 interaction focused on germline encoded
regions of the Vg9 IgV domain. This implied that the BTN2A1-
Vg9Vd2 interaction might be analogous to BTNL3 binding to
human Vg4+ TCRs (Melandri et al., 2018; Willcox et al., 2019),
which is similarly focused on germline-encoded regions of the
Vg4 chain and allowed us to model BTN2A1-Vg9 interaction
based on the proposedBTNL3-Vg4 interactionmode (Figure 3C).
An initial homology model suggested strong feasibility of a
similar interaction mode and highlighted seven amino acids on
the face of the BTN2A1 IgV domain incorporating the C, C’, F
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Figure 3. Direct BTN2A1 Binding to Germline-Encoded Regions of Vg9 Is Essential for P-Ag Sensing
(A) (Top panel) Injection of BTN2A1 IgV (25 mM) over surfaces with immobilized Vg9Vd2 TCR (2,457 resonance units (RU)) and control surfaces comprising Vg4Vd5
TCR (2,351 RU), Vg2Vd1 TCR (1,800 RU), or streptavidin alone. Notably, signals over streptavidin alone and control TCR surfaces are equivalent. (Bottom panel)
Injection of BTN2A1 IgV (24 mM) over surfaces with immobilized G115 (Vg9Vd2; 3,109 RU), MOP (Vg9Vd2; 3,108 RU), and Vg9Vd1 (2,774 RU) TCRs and LES TCR
control (Vg4Vd5; 2,885 RU).
(B) Equilibrium affinitymeasurements and Scatchard analysis (inset) of BTN2A1 IgV binding to the G115 (Kd = 39.5 mM) andMOP (Kd = 48.4 mM) Vg9Vd2 TCRs and
Vg9Vd1TCR (Kd = 47.9 mM).
Data in (A) and (B) are representative of eight to nine independent experiments.
(C) Model of the BTN2A1-Vg9 interaction mode based on the proposed BTNL3-Vg4 interaction, with expanded panel showing potential contacts at the Vg9-
BTN2A1 IgV interface.
(D) Effects of seven alanine substitutions in proposed BTN2A1 interface residues on Vg9Vd2 TCR interaction, indicating affinity of mutant BTN2A1 relative to WT
BTN2A1 calculated in the same experiment. Data shown are representative of two independent experiments.
(E) Effects of BTN2A1 R124A and R124E mutations on IL-2 production by TCR-MOP in response to HMBPP-treated BTN3A1 and BTN2A1 expressing CD80+
CHO cells.
(F) Predicted involvement of Vg9 HV4 and CDR2 residues in BTN2A1 interaction.
(G) Effects of Vg9-E70 mutation (HV4) on IL-2 production by TCR-MOP in response to HMBPP-treated BTN3A1 and BTN2A1 expressing CD80+ CHO cells.
(legend continued on next page)
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andG b strands (CFG face), equivalent to the region of BTNL3 IgV
domain involved in binding Vg4, as candidates for alanine muta-
tion (Figure 3C). Individual BTN2A1 alanine mutants were gener-
ated for these seven residues. Of these, four completely abro-
gated BTN2A1 binding to Vg9Vd2 TCR (R65A, R124A, Y126A,
E135A), a fifth marginally decreased affinity (K79A), Y133A did
not affect binding, andS72A increased affinity (Kd 10–15 mM) (Fig-
ures 3D and S3B). These results allowed generation of an
improved, mutationally informed model of BTN2A1/Vg9 interac-
tion using the high-ambiguity driven protein-protein DOCKing
(HADDOCK) software, analysis of which outlined a molecular
rationale for the effect of each mutation (Figure S3C; STAR
Methods). Based on comparison of the BTN2A2 IgV sequence
(Figure S3D) and a BTN2A2 homology model (Figure S3E) in the
context of this BTN2A1 model, we predicted that BTN2A2 IgV
would also be competent for Vg9 TCRbinding, which was subse-
quently confirmed using SPR for both Vg9Vd2 TCRs (Figures S3F
and S3G) and a Vg9Vd1 TCR (Figures S3G and S3H), which indi-
cated a similar affinity to BTN2A1 (Kd 39–50 mM [n = 3]).
To assess the dependence of the functional activity of BTN2A1
on TCR binding, we transduced CHO-BTN3A1 cells with the
BTN2A1 R124A mutation shown to abrogate Vg9+ TCR binding
(and also a BTN2A1 R124E charge-reversal mutant) and as-
sessed effects on Vg9Vd2-mediated P-Ag response. Although
permissive for cell-surface BTN2A1 expression (Figure S3I),
both mutations completely abrogated both P-Ag-dependent
IL-2 production and basal P-Ag-independent BTN2A1-mediated
responses (Figure 3E). Furthermore, BTN2A1 R65A and Y126A
mutations that eliminated Vg9+ TCR-BTN2A1 interaction also
abrogated P-Ag-dependent and independent responses (Fig-
ure S3J). However, although mCherry reporter signal was de-
tected for each construct, it must be noted that these mutant
proteins could not be detected using the anti-BTN2A1 mAb (Fig-
ures S3K and S3L). We therefore could not exclude the possibil-
ity that these mutations affected cell-surface expression,
although alternatively, they could be important components of
the anti-BTN2A1 mAb epitope.
The mutationally guided model also indicated involvement of
multiple TCR residues in the HV4 (including E70, I74, E76, T77,
T79) and CDR2 (G56, T57, V58) loops of the Vg9 IgV domain in
BTN2A1 interaction, regions also critical for BTNL3-Vg4 interac-
tion (Willcox et al., 2019) (Figure 3F). Consistent with this,
Vg9Vd2-expressing hybridomas bearing mutations at TCRg HV4
E70 eliminated BTN2A1-dependent P-Ag-independent IL-2 pro-
duction and substantially affected TCR-dependent P-Ag re-
sponses, with E70K exhibiting severely reduced activation poten-
tial (Figure 3G). Although the BTN2A1-Vg9 model was supported
by our BIAcore data (Figure 3A) in indicating no role for Vd in
BTN2A1 recognition, we sought to establish whether BTN2A1-
dependent P-Ag sensing was nevertheless affected by Vd2 CDR
loops by generating TCR hybridomas bearing either a CDR3 dele-
tion of TCR-MOP (DCDR3) (Figure S3B) or a R51A substitution in
CDR2 (Li, 2010). Each mutation abolished both P-Ag-dependent(H) Effects of mutations in Vd2CDR2 (R51A) or a deletion in CDR3 (DCDR3) on IL-2
expressing CD80+ CHO cells.
In (E), (G) and (H), error bars indicate standard deviation for three independent stim
response obtained from CHO cells expressing both BTN2A1 and BTN3A1 in the p
(H) were significant, except for TCR-MOP E70A at 1 mM. See also Figure S3.
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responses (Figure 3H).
Collectively, these findings established that Vg9Vd2 TCR
binds BTN2A1 IgV via a binding mode that closely mimics that
of Vg4 TCR for BTNL3 and that this binding is essential for
P-Ag sensing but occurs alongside parallel and essential Vd2
CDR-mediated binding events.
BTN2A1 Can Form Disulphide-like Homodimers at the
Cell Surface
BTN andBTNLmolecules have been shown to form either homo-
or heterodimers (Palakodeti et al., 2012; Vantourout et al., 2018).
To investigate BTN2A1’s propensity for dimer formation, we car-
ried out homology modeling of BTN2A1 IgV-C (Figures 4A and
4B) based on superposition of BTN2A1 onto the structure of
the BTN3A1 V-shaped homodimer (Palakodeti et al., 2012). In-
spection of the model confirmed a viable IgC-IgC homodimer
interface driven bymain-chain-main-chain hydrogen bonding in-
teractions supplemented by side-chain-dependent hydrophobic
contacts; these were predicted to be broadly equivalent to those
of BTN3A1 IgC-IgC, albeit with increased interchain hydropho-
bic contacts in BTN2A1 (M153, F235) versus BTN3A1 (V154,
S236), indicating a strong potential for non-covalent dimer for-
mation (Figure S4A); in addition, further analyses indicated a
similar potential for heterodimer formation with other members
of the BTN family (Figure S4B).
Interestingly, the BTN2A1 IgV-C model also highlighted close
proximity of extracellular membrane-proximal cysteine residue
(C247) with its equivalent residue in the opposing monomer (Fig-
ure 4B), suggesting that the homodimer might be stabilized addi-
tionally by an interchain disulphide bond; of note, this cysteine is
lacking in all other BTN and BTNL molecules (Figure S4C).
Indeed, SDS-PAGE and immunoblot-streptavidin detection of
BTN2A1 under reducing and non-reducing conditions confirmed
that the overwhelming majority of cell surface BTN2A1 was pre-
sent as a disulphide-bonded dimer (Figure 4C), even in the pres-
ence of BTN3A1 and in the presence and absence of Zol (Fig-
ure S4D), consistent with the BTN2A1 homodimer model
(Figures 4A and 4B). However, transduction of BTN2A1 bearing
a C247W mutation did not affect P-Ag-dependent or P-Ag-inde-
pendent basal IL-2 production (Figure 4D); therefore, any disul-
phide stabilization may be redundant owing to strong existing
non-covalent homodimer potential. In contrast, BTN2A2, which
lacks this cysteine residue, did not form disulphide-linked dimers
(Figure 4C), but analogous structural modeling indicated equiva-
lent propensity for non-covalent IgC-IgC-mediated homodimer
formation (Figure S4E).
Finally, by combining our HADDOCK-derived model of
Vg9Vd2/BTN2A1 interaction (Figure S3B) with our BTN3A1-
based homology model of the BTN2A1 homodimer (Figure 4A),
we were able to envisage how BTN2A1 recognition might take
place at the cell surface (Figure 4E). Notably, the Vg9Vd2 TCR-
BTN2A1 interaction mode can in principle allow clustering ofproduction by TCR-MOP in response to HMBPP-treated BTN3A1 and BTN2A1
ulation experiments. Percentage activation is normalized against themaximum
resence of 1 mMHMBPP. Differences betweenWT and mutants in (E), (G), and
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Figure 4. BTN2A1 Forms Disulphide-Linked Homodimers at the Cell Surface
(A) Homology model of BTN2A1 homodimer.
(B) C-terminal region of BTN2A1 homology model indicating close proximity of Cys residues.
(C) Non-reducing (NR) or reducing (R) SDS-PAGE analysis of CHO-cell expressed BTN2A1 and BTN2A2 protein.
(D) Effects of BTN2A1C247Wmutation on IL-2 production by TCR-MOP in response to HMBPP-treated CD80+ CHO cells expressing BTN2A1 and BTN3A1. Error
bars indicate standard deviation for three independent stimulation experiments. Percentage activation is normalized against the maximum response obtained
from CHO cells expressing both BTN2A1 and BTN3A1 in the presence of 1 mM HMBPP.
(E) Model of Vg9Vd2-BTN2A1 interaction incorporating BTN2A1 homodimer formation, and bilateral Vg9Vd2 interaction with BTN2A1 IgV domain.
See also Figure S4.two TCRs for each BTN2A1 homodimer, each with somatically
recombined CDR3 loops implicated in P-Ag sensing oriented
directly toward the target cell surface.
BTN2A1 Is Closely Associated with BTN3A1 at the Cell
Surface
To assess whether BTN2A1 and BTN3A1 were associated with
each other at the cell surface either before or after P-Ag expo-
sure, a membrane-impermeable amine-reactive cross-linker
incorporating a 16A˚ spacer was used to cross-link proteins on
the surface of CHO transductants co-expressing C-terminally
HA-tagged BTN2A1 (BTN2A1-HA) and a N-terminally FLAG-tagged BTN3A1 (FLAG-BTN3A1). Immunoprecipitation (IP) us-
ing anti-HA beads or 20.1 mAb and subsequent anti-FLAGwest-
ern blot (WB) was used to detect cross-linked BTN2A1-BTN3A1
species (Figure 5).
Following IP of BTN2A1-HA using anti-HA beads and subse-
quent WB detection of FLAG-BTN3A1 under reducing condi-
tions using an anti-FLAG antibody, two discrete bands were
detected that considerably exceeded the size of either
BTN2A1 or BTN3A1 monomers (observed molecular weights
[MWs] 55k Da, FLAG-BTN3A1; 70 kDa, BTN2A1-HA) (Fig-
ure 5A); each was only detected in the presence of cross-linker.
One band was 130 kDa, equivalent to cross-linking of a singleImmunity 52, 487–498, March 17, 2020 493
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Figure 5. Cell-Surface Association of BTN2A1 and BTN3A1 Proteins
(A) Anti-BTN2A1-HA immunoprecipitation, combined with anti-BTN3A1-FLAG western blot detection, following cell-surface cross-linking of CHO cells
expressing BTN2A1-HA, FLAG-BTN3A1, or both.
(B) Anti-BTN3A1 IP (20.1 mAb) of the same lysate combined with anti-BTN3A1-FLAG detection.
For (A) and (B), likely monomeric or oligomeric species corresponding to appropriate molecular weight bands are indicated on the right-hand side. Data are
representative of four independent experiments.
(C) NMR chemical-shift perturbations (CSPs) in selected residues in 1H-15N-labeled BTN3A1 IgV (100 mM) following addition of BTN2A1 IgV (100 mM).
(D) Graph of chemical shift versus residue number in BTN3A1 IgV. Threshold levels for significant CSPs are indicated by horizontal lines.
(E) Mapping of residues whose amide resonances undergo CSPs on the surface of BTN3A1 IgV domain, showing clustering in the CFG face of the domain.
Residues are colored in relation to the size of their CSPs, using the thresholds indicated in (D).
See also Figure S5.
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BTN2A1 monomer and BTN3A1 monomer (125 kDa expected
MW). A second represented a considerably larger cross-linked
species (exceeding the weight of the 180 kDa marker), most
likely equivalent to one BTN2A1 homodimer and one BTN3A1
homodimer (250 kDa) (Figure 5A). In addition, both bands
were also detected when the BTN3A1-specific mAb 20.1 was
used for the initial immunoprecipitation step (Figure 5B),
including when polyclonal anti-BTN2A1 antibody was used for
WB detection (Figure S5). Incubation of CHO transductants
with Zol was also used to assess if the presence of cross-linked
BTN2A1-BTN3A1 specieswas dependent upon P-Ag levels (Fig-
ures 5A, 5B, and S5A). Of note, both higher-MW BTN2A1-
BTN3A1 bands were detected in the presence and absence of
Zol (Figures 5A, 5B, and S5A), indicating BTN2A1 association
with BTN3A1 occurs constitutively.
To investigate whether BTN2A1-BTN3A1 association involved
IgV-IgV domain interactions, we expressed and purified 1H-15N-
labeledBTN3A1 IgV inE. coliandperformed 1H-15N heteronuclear
single quantum coherence (HSQC) spectroscopy in the absence
and presence of an equimolar amount of naturally labeled
E. coli-expressedBTN2A1 IgV (Figures 5C–5Eand S5B). Analyses
were facilitated by our previous assignment of all amide residues
of the BTN3A1 IgV domain (Salim et al., 2017) and demonstrated
small but significant chemical-shift perturbations (CSPs) in
numerous BTN3A1 residues in the presence of BTN2A1 IgV (Fig-
ures 5C and 5D), indicating direct interaction. Mapping these
CSPs onto the BTN3A1 IgV domain structure indicated the major-
ity of these residues clustered around theCFG faceof theBTN3A1
domain (Figure 5E). Importantly, this region of BTN3A1 or BTN3A2
(which share an identical IgV domain) has been highlighted as crit-
ical for P-Ag sensitization (Willcox et al., 2019), including specif-
ically Y127, K136, and R73; notably, we show that both Y127
and K136 displayed detectable chemical shifts upon BTN2A1
binding, as did S70, S71, and Q74. In contrast, no CSPs were de-
tected in similar experiments using 1H-15N-labeled BTN3A1
following addition of a control BTN family IgV domain (unlabeled
BTNL3; Willcox et al., 2019) (Figures S5C and S5D). These results
indicate that IgV-IgVdomain interactions involving theCFG faceof
BTN3A1 or BTN3A2 contribute to BTN2A1-BTN3A1 association.
DISCUSSION
Here, we identified BTN2A1 as Factor X via a radiation hybrid
approach that highlighted a critical 580 kb region of Chr 6, in
which we probed candidate genes that were retained in species
that bear Vg9Vd2 T cells but were missing or non-conserved in
mouse. BTN2A1-transduced rodent cells were specifically
stained by Vg9Vd2 TCR tetramers, and crucially, BTN2A1 ex-
hibited strong functional synergy with BTN3A1, restoring P-Ag
sensing following co-transduction intomouse cells.Moreover, us-
ing SPR,wewere able to demonstrate specific binding of BTN2A1
IgV domain to Vg9Vd2 TCRs. In addition, target cells transduced
with BTN2A1 molecules incorporating single amino acid muta-
tions that eliminated Vg9Vd2 TCR binding in SPR experiments
failed to stimulate P-Ag-specific effector responses in Vg9Vd2
T cells. These findings not only establish BTN2A1 as the putative
Factor X co-factor in P-Ag sensing but also highlight that its role as
a direct ligand for the Vg9Vd2 TCR is essential to its ability to
potentiate P-Ag sensing. Of note, Rigau et al. recently also identi-fied BTN2A1 as a critical mediator of P-Ag sensing and a direct
ligand for Vg9+ TCRs using a TCR-tetramer staining and
CRISPR-screen approach (Rigau et al., 2020).
Our results highlight the potential of radiation hybrids as a test
system for identification of genomic regions controlling cellular
phenotypes and function. The relatively simple screening scheme
for identification of these regions by comparison of radiation
hybrid transcriptomes facilitates the generation of custom-made
radiation hybrids, which is an advantage over genetically defined
radiation hybrid panels (Ross, 2001). Moreover, enabling rodent
cells with capacity for P-Ag sensitization will not only help to un-
derstand Vg9Vd2 T cell function in vitro but also aid in establishing
much-needed small animal models for the study of P-Ag-reactive
cells. The De Libero group had shown (Kistowska, 2007) that
Vg9Vd2 TCR transgenic mouse cells exhibit a block in thymic
maturation, which can be overcome by administration of anti-
CD3 antibody, suggesting a positive selection signal provided
by species-specific molecules. We hypothesize that BTN2A1
and/orBTN3A1 are suchmolecules and aim to testwhether in vivo
expression of BTN2A1 and/or BTN3A1 enables Vg9Vd2 T cell
maturation. If established, such a model would allow the determi-
nants controlling gd T cell responses and functionality in the
emerging Vg9Vd2 T cell compartment to be studied and impor-
tantlywould allow for development of small animalmodels for har-
nessing Vg9Vd2 T cells in pathological conditions such as cancer
and infections with Vg9Vd2 T cell activating pathogens.
Establishment of direct binding experiments enabled us to
probe the interaction mode of BTN2A1 with the Vg9Vd2 TCR.
Our finding that TCR binding to BTN2A1 is solely dependent
upon the TCR Vg9 chain is entirely consistent with the finding
that Vd2 T cells expressing alternative non-Vg9 Vg regions are
both insensitive to P-Ag and also adopt an adaptive-like biology
fundamentally distinct from the innate-like features of Vg9Vd2
T cells (Davey et al., 2018). However, it was initially surprising,
given that previous studies have highlighted the importance of
multiple CDRs of both Vg9 and Vd2 TCR chains (including
CDR3g and CDR3d) to Vg9Vd2-mediated P-Ag sensing (Wang
et al., 2010); moreover, our mutagenesis studies provided addi-
tional confirmation of the importance of CDR3d and CDR2d resi-
dues for BTN2A1-stimulated P-Ag sensing. Furthermore, the
exclusive focus of BTN2A1 on Vg9 raised the question of whether
the Vg9Vd2-BTN2A1 interactionmodewas related to that of intes-
tinal Vg4 T cell recognition of BTNL3.8 (Willcox et al., 2019), which
involves germline-encoded CDR2 and HV4 regions of the Vg4
TCR chain and the CFG face of the BTNL3 IgV domain. Modeling
and mutagenesis approaches confirmed a fundamental similarity
with this binding mode, indicating both CDR2 and HV4 regions of
the Vg9 TCR chain, and residues in the CFG face of BTN2A1were
critical for recognition. These results highlight clear evolutionary
conservation of the ‘‘superantigen-like’’ BTN or BTNL-gd TCR
interaction mode across different anatomical sites, which will no
doubt be elucidated further by future structural analyses.
The oligomerisation state and interaction partners of BTN2A1
on the target cell surface are likely important factors in its mode
of action. Specifically, we show that cell surface BTN2A1 is
comprised predominantly of homodimers in transduced rodent
cells and 293T cells. This is consistent with structural work that
highlighted the potential of BTN3A1 to form IgC-IgC homo-
dimers (Palakodeti et al., 2012), and indeed, our modelingImmunity 52, 487–498, March 17, 2020 495
studies confirmed that BTN2A1 homodimers are likely to form
highly equivalent IgC-IgC interactions. However, our results
highlight the potential of BTN2A1 homodimer stabilization via
an interchain disulphide-linkage involving a membrane-proximal
cysteine residue absent in BTN2A2 and BTN3 molecules. Com-
bined with our successful production of BTN2A1 IgV as a soluble
functional monomeric domain, this suggests that BTN2A1 may
form a ‘‘Y-shaped’’ dimer analogous to that proposed for
BTN3A1 homo- and heterodimers (Palakodeti et al., 2012; Van-
tourout et al., 2018) and BTNL3.8 and BTNL1.6 heterodimers
(Melandri et al., 2018; Willcox et al., 2019). Nevertheless, an
important caveat is that although our studies suggest BTN2A1
preferentially homodimerizes even when co-expressed along-
side BTN3A1, conservation of residues at the IgC interface
means we cannot exclude non-disulphide-stabilized IgC-IgC-
mediated heterodimeric interactions with other BTN molecules,
including potentially BTN2A2 or, alternatively, BTN3A2 or
BTN3A3 (Vantourout et al., 2018).
Importantly, we also establish a close association between
BTN2A1 and BTN3A1 on target cells. While these results are
consistent with those of Rigau et al., who determined co-localiza-
tion of BTN2A1 and BTN3A1 towithin the 10-nm resolution limit of
FRET detection (Rigau et al., 2020), our immunoprecipitation
approach employed a membrane-impermeable cross-linker
featuring a 16-A˚ spacer arm, thereby suggestive of a close,
possibly direct association at the cell surface. While importantly
these experiments defined discrete, higher-MW species incorpo-
rating both BTN2A1 and BTN3A1, the requirement for chemical
cross-linking to immunoprecipitate such complexes suggests
the association is likely of relatively low affinity. Consistent with
a direct interaction, our nuclear magnetic resonance (NMR)
studies indicate that IgV-IgV interactions likely contribute to this
cis-BTN2A1-BTN3A1 association and corroborate recent muta-
genesis results (Willcox et al., 2019) that highlighted a critical
role for residues on the CFG face of BTN3A1 or BTN3A2 IgV in
P-Ag sensing. An interesting precedent for involvement of this
CFG face in IgSF interactions in cis is provided by a recent study
by Chaudhri and colleagues, who showed that PD-L1 may simi-
larly utilize the CFG face of its IgV domain to mediate cis-interac-
tions with B7.1 (Chaudhri et al., 2018). Notably, similar immuno-
precipitation results were obtained in the presence or absence
of Zol, which stimulates P-Ag accumulation in target cells, indi-
cating that while likely essential for P-Ag sensing, BTN2A1-
BTN3A1 association per se may not provide the critical molecular
signal for Vg9Vd2 activation. Of relevance, the potential for
BTN3A1 to heterodimerize with BTN3A2 or BTN3A3 and promote
optimal P-Ag sensing (Vantourout et al., 2018), the identical IgV
domain sequences ofBTN3A1andBTN3A2, and recentmutagen-
esis results on BTN3A1 and BTN3A2 (Willcox et al., 2019) are
important considerations in interpreting these results and suggest
that BTN2A1 IgV interactions with BTN3 could involve IgV do-
mains of different BTN3 family members.
Collectively, our results and those of Rigau et al. (2020) revise
current models of P-Ag sensing, many of which have previously
focused on BTN3A1 as a ‘‘lone TCR ligand,’’ and proposed
either direct presentation of P-Ag by the IgV domain (Vavassori
et al., 2013) or ‘‘inside-out’’ models whereby binding of P-Ag to
the intracellular BTN3A1 B30.2 domain is transmitted in some
way to the extracellular region of BTN3A1, creating a TCR bind-496 Immunity 52, 487–498, March 17, 2020ing site (Sandstrom et al., 2014; Wang et al., 2013). Importantly,
our results do not exclude the possibility of direct TCR-BTN3A1
interactions, and indeed, recent mutagenesis of BTN3A1 and
BTN3A2 (Willcox et al., 2019) could be interpreted as support-
ing Vg9-BTN3A1 or BTN3A2 binding using a mode similar to
both Vg4-BTNL3 and Vg9-BTN2A1. Nor can we discount
the possibility of parallel and/or sequential interaction of Vg9
TCR with BTN2A1 or BTN3A1 IgV domains. However, the un-
equivocal demonstration by our study and by Rigau et al.
(2020) of direct Vg9-BTN2A1 interaction, combined with
lack of any compelling evidence for direct TCR-BTN3A1 or
TCR-BTN3A2 interaction and finally our detection of direct
BTN2A1-BTN3A1 complexes in this study, point to alternative
possibilities. Taken together, these observations strongly sug-
gest a composite ligand model of Vg9Vd2 recognition involving
coordinate Vg9-germline-mediated interaction with BTN2A1
alongside a CDR3-mediated interaction with a separate
ligand(s). The identity of such a TCR ligand and its potential
association partners at the cell surface is currently a focus of
investigation. One possibility that cannot be excluded is that
BTN3A1 is itself recognized in complex with BTN2A1 following
P-Ag exposure, although our demonstration of constitutive
BTN2A1-BTN3A1 association might argue against this; given
that BTN2A1-BTN3A1 complexes occur in the absence of
P-Ag, this would still require an inside-out mechanism to
configure complexes for productive TCR-mediated recogni-
tion. Alternatively, it is tempting to speculate that BTN3A1
could function (potentially with facilitation by BTN3A2 or
BTN3A3) to chaperone a critical additional Vg9Vd2 TCR ligand
to the surface to be coordinately recognized as part of a
BTN3A1-ligand complex in a CDR3-mediated fashion along-
side BTN2A1. One prediction of this model is that such a
CDR3-recognized ligand(s) is likely to be highly conserved be-
tween humans and rodents. Of note, instead of invoking direct
BTN3A1 IgV interaction with the Vg9Vd2 TCR, this second
model proposes BTN3A1 association with BTN2A1 as a mech-
anism of recruiting another ligand to the complex following
P-Ag exposure; this would allow the Vg9Vd2 T cell compart-
ment to continually survey BTN3A1-BTN2A1 complexes for
the presence of a P-Ag-regulated ligand. In this context, along-
side Vg9 interaction with BTN2A1, such BTN3A1-BTN2A1
interactions most likely serve to spatially orientate BTN3A
homo- or heterodimers and, following P-Ag exposure, an asso-
ciated ligand, appropriately for TCR CDR3-mediated recogni-
tion. In this second composite ligand model, P-Ag binding to
BTN3A1 B30.2 could regulate the strength of BTN3 association
with such a ligand, and/or trafficking of such complexes to the
cell surface. Further studies are required to clarify such mech-
anistic models, define structural features of the key interac-
tions, address issues such as the role of BTN2A1 B30.2
domain, and establish relevance to other gd T cell subsets,
including the intestinal Vg4 compartment.
In summary, we show that by acting as a direct ligand for the
Vg9Vd2 TCR, BTN2A1 powerfully synergizes with BTN3A1 to
potentiate P-Ag sensing. Vg9Vd2 T cells have to date been the
primary focus of therapeutic development for gd T cells. Under-
standing their mode of action should facilitate attempts to
harness them therapeutically for either cell therapy or small
molecule approaches.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
CHO, CHO-chr6, BW, A23, 53/4 hybridoma TCR transductants, and radiation hybrids (CHO Chr6 – rodent fusion hybrids) were
cultured with RPMI (GIBCO) supplemented with 10% FCS, 1 mM sodium pyruvate, 2.05 mM glutamine, 0.1 mM nonessential amino
acids, 50 mM b-mercaptoethanol, penicillin (100 U/mL) and streptomycin (100 U/mL). Peripheral blood mononuclear cells isolated
from healthy volunteers were also maintained as above with or without rhIL-2 (Novartis Pharma). 293T cells were maintained in
DMEM (GIBCO) supplemented with 10% FCS.
METHOD DETAILS
Generation of radiation hybrids
CHO Chr 6 (106 or 107 cells) were irradiated at Faxitron CP160 (program 160 kV, 6.3 mA, 300 Gy: 60 min, 100 Gy: 20 min). The irra-
diated cells and fusion partner (BW or A23) were mixed at 1:1 or 1:3 ratio (irradiated cell:fusion partner) and centrifuged at 461 g for
5 min at RT. The cell pellet was gently tapped and 1mL PEG1500 was added slowly over a minute with gentle mixing in a prewarmed
water-bath. After addition of PEG, cells were resuspended in 50 mL warm serum free RPMI and incubated for 30 min, followed by
centrifugation at 461 g for 5 min and careful resuspension in RPMI supplemented with 10% FCS at 104 cells/mL. The cell suspension
was seeded in 96well plate flat bottom (A23 fused) or round bottom (BW fused) plates in 100 ml per well. On the following day, 100 ml of
2X HAT was added and cells were selected for two weeks. The selected clones were supplemented with HT medium and further
seeded at limiting dilutions to obtain single cell clones which were tested for P-Ag mediated activation of our Vg9Vd2 TCR (MOP)
transductants. P-Ag presentation capable and incapable clones were PCR characterized for human Chr 6 regions with primers listed
in Table S1.
RNAseq analysis of Radiation Hybrids
Knowing the differences in antigen presentation of the various radiation hybrid cell lines, we performed RNA seq to identify those
human Chr 6-encoded genes that are expressed in each hybrid line. Cells were stored in TRIzol Reagent (Invitrogen) and total
RNA was extracted. Sequencing libraries were produced with an Illumina Truseq RNA preparation kit as described by the supplier’s
protocol and were sequenced with an Illumina HiSeq4000. Sequence reads were mapped to the human genome (hg38) with STAR
(version STAR_2.50a) and read counts of gene transcripts were determined using gtf file Homo_sapiens.GRCH38.84.gtf and featur-
eCount (v1.5.0-p1). Cell lines were then compared for presence, i.e., expression, of human Chr 6 genes. To filter out reads descend-
ing from mouse or hamster cells, all fastq-files were initially mapped against the mouse genome (Mus musculus, version GRCm38)
using STAR and the corresponding Gene Transfer Format (gtf) file (version 87). Unmapped reads and those exhibiting more than two
mismatches were selected and mapped against the Chinese hamster genome (Cricelulus griseus, version 1). The corresponding gtf-
file was downloaded from the pre-Ensembl ftp site (Cricetulus_griseus.CriGri_1.pre.gtf). Afterward, all unmapped reads and those
containing more than two mismatches were again selected to finally map against the human genome (version hg38; gtf-file version
84). Only reads showing maximally one mismatch were considered as true. With the help of featureCounts, mapped reads were
assigned to genomic features using the above mentioned gtf-files. The results were summarized within an Excel-file. Further gene
information were extracted from BioMart (Ensembl Genes 84; (Smedley et al., 2015).
In vitro stimulation with human Vg9Vd2 TCR transductants
For in vitro stimulations, 104 CHO or 293T cells were seeded on day 1 with 50 mL RPMI or DMEM in a 96 well flat bottom cell culture
plate and cultured over-night. On day 2, 50 mL of 5x104 - 53/4 hybridoma cells expressing the humanMOPVg9Vd2 TCR and 100 mL of
appropriate stimulant such as HMBPP, Zol, or 20.1mAbwere added to the culture and incubated for 22 h. After overnight incubation,
the activation of TCR transductants was analyzed by measurement of mouse IL-2 from the supernatants of the co-cultures by ELISA
(Invitrogen) as per manufacturer’s protocol.
Expansion of primary human polyclonal Vg9Vd2 T cells
Fresh peripheral blood mononuclear cells (PBMCs) were isolated from healthy volunteers after obtained written informed consent in
accordance with the Declaration of Helsinki and approval by the University of W€urzburg institutional review board. Whole blood was
layered over the Histopaque-1077 in a 50 mL falcon tube and centrifuged at 400 g for 30 min at room temperature (RT) with no ac-
celeration and brakes. After centrifugation, the opaque interface containing PBMCs were aspirated and washed twice at 461 g for
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human IL-2 100 IU/mL (Novartis Pharma) in 106 cells/mL density in a 96 well U bottom plate for 10 days with 100 mL per well. After
10 days, cells were pooled and washed twice and cultivated to rest without rhIL- 2 at 106 cells/mL density in a 6-well plate. After three
days, rested cells were subjected for further experiments.
Generation of 293T BTN2–/– cell lines
BTN2A1 and BTN2A2 genes were disrupted in 293T cells using CRISPR. The CRISPR sequencing targeting functional BTN2A genes
were designed with the help of online tools mentioned in the table (software section) and sequences were cloned into GeneArt
CRISPR Nuclease vector as per manufacturer’s instructions. On day1, 1.53 106 293T cells were seeded in a 6 cm cell culture plate
with DMEMmedium without pyruvate (10% FCS). On day 2, cells were transfected with 5 mg of BTN2A-IgV_CRISPR cloned GeneArt
CRISPR Nuclease (CD4 enrichment) Vector or BTN2A1_49FCRISPR cloned GeneArt CRISPR Nuclease (OFP Reporter) Vector or
BTN2A2_343CRISPR clonedGeneArt CRISPRNuclease (CD4 enrichment) Vector in a calcium-phosphate dependent method (Sam-
brook and Russell, 2006) (CRISPR sequences are provided in Table S2). 48 h post transfection, the highest reporter expressing (top
3%) cells were sorted and seeded at 1 cell/200 mL medium/well in 96 well plate flat bottom cell culture plate and cultivated till single
cell derived clones were visible. Such clones were tested for their capacity to stimulate our 53/4 hybridoma human Vg9Vd2 TCR
(MOP) TCR transductants in the presence of 1 mMHMBPP. The clones which exhibited loss of function were subjected to DNA isola-
tion, followed by PCR for the amplification of genetic loci targeted by CRISPR sequences with appropriate genomic primers (Table
S2) complementary to flanking regions of CRISPR target site. The PCR products were cloned into TOPO-TA vector (Invitrogen) and
the TOPO-TA clones were analyzed by sequencing for the presence of in/del mutations resulting in loss of gene mutation as shown
below. 293T BTN2/ cell line harbor BTN2A1 alleles with 10 and 16 nucleotide deletion, BTN2A2 alleles with 1 and 10 nucleotide
deletions; 293TBTN2A1/ harborsBTN2A1 alleles with 1 nucleotide addition and 10 nucleotide deletion; 293TBTN2A2/ harbors
BTN2A2 alleles with 1 nucleotide deletion.
CRISPR target sites and allelic phenotypes
1a) BTN2/ allelic phenotype
BTN2A1 IgV CRISPR target site
2A1IgV GCAGTGTTTGTGTATAAAGGTGGCAGAGAGAGAACAGAGGAGCAGATGGAGGAGT 55
2A1allele1 GCAGTGTTT——————————-GTGGCAGAGAGAGAACAGAGGAGCAGATGGAGGAGT 45
2A1allele2 GCA————————————————-GTGGCAGAGAGAGAACAGAGGAGCAGATGGAGGAGT 39
*** ************************************
1b) BTN2A2 IgV CRISPR target site
2A2IgV GCAGTGTTTGTGTATAAGGGTGGGAGAGAGAGAACAGAGGAGCAGATGGAGGAGT 55
2A2allele1 GCAGTGTTTGTGTATA-GGGTGGGAGAGAGAGAACAGAGGAGCAGATGGAGGAGT 54
2A2allele2 GCAGTGTTTG——————————TGGGAGAGAGAGAACAGAGGAGCAGATGGAGGAGT 45
********** ***********************************
2) BTN2A1/ allelic phenotype
2A1-49F GGACTAGGCTCTAAGCCCCTCATTTCAATGAGGGGCCATGAA-GACGGGGGCATCCGGC 59
Allele1 GGACTAGGCTCTAAGCCCCTCATTTCAATGAGGGGCCATGAAGGACGGGGGCATCCGGC 59
Allele2 GGACTAGGCTCTAAGCCCCTCATTTCAATGAGGGG——————————————GGCATCCGGC 45
*********************************** **********
3) BTN2A2/ allelic phenotype
2A2 CAAGAAGGCAGGTCCTACGATGAGGCCATCCTACGCC-TCGTGGTGGCA 48
Allele CAAGAAGGCAGGTCCTACGATGAGGCCATCCTACGCCCTCGTGGTGGCA 49
************************************* ***********
Human IFNg assay
293T or 293TBTN2/ cells were seeded overnight in triplicates at 23 104 cells/well in 100 mLDMEMcontaining 10%FCS in a 96well
flat bottom cell culture plate with or without 25 mMZol. Next day, DMEMwith/without Zol was aspirated and cells were washed twice
with PBS at RT and 23 104 expanded Vg9Vd2 T cells/well in 100mL RPMI was added and cocultured for 4 h. After 4 h, supernatants
were collected and frozen at20C, until cytokine assay was performed with human IFNg ELISA kit (Invitrogen) was used according
to the manufacturer’s instructions.
Cloning and expression of BTN2A1, BTN2A2 or mutants
The full length human BTN2A1 and BTN2A2were amplified from the cDNA obtained from 293T cells with the help of pMIM-BTN2A1/
2Fwd and pMIM-BTN2A1/2Rev primers (see Table S2) using Phusion DNA polymerase (Thermo Scientific). The amplified BTN2A1 or
BTN2A2 PCR products were cloned into EcoRI & BamHI digested pMIM or pMIG II vector via In-Fusion HD cloning kit (Takara).
BTN2A1 mutants were generated by fusion of two PCR products obtaining from pMIM-BTN2A1Fwd/Mutant-Rev and Mutant-
Fwd/pMIM- BTN2A1/2Rev and cloned as above. Such cloned BTN2 genes and their corresponding mutants were expressed in
target cells through retroviral transduction (Soneoka et al., 1995).e4 Immunity 52, 487–498.e1–e6, March 17, 2020
Generation of FLAG/HA tagged BTN3A1 and BTN2A1
For the N terminus FLAG or HA tagged proteins, FLAG or HA tag was inserted into the BamHI+EcoRI digested pIH or pIZ vector back
bone with digested FLAG/HA Fwd and Rev oligonucleotide sequences with appropriate restriction sites and linker sequences
flanking the FLAG/HA tag sequences. BTN3A1 and BTN2A1 full length amplicons without leader peptide were amplified either
cDNA or above mentioned pMIM-BTN2A1 as template. BTN2A1-HA tagged constructed amplified with pMIM-BTN2A1 as template
and pIZ-BTN2A1Fwd and BTN2A1- HA-Rev primers was cloned into pIZ vector backbone via In-Fusion-HD cloning as per manufac-
turer’s protocol.
Generation of Vg9Vd2 TCR (MOP) and mutant TCR chains
Vg9Vd2 TCR (MOP), Vd2-R51A and Vd2-CDR3 deletion mutant (DCDR3: CDR3d sequence CACD——–YTDKLIF) TCR chains were
generated as reported earlier (Li, 2010; Starick et al., 2017). Vg9-E70A, -E70R and -E70K mutants were generated by fusion of two
PCR products amplified by MOP- Vg9 Fwd/Mut-Rev and Mut-Fwd/ MOP-Vg9-Rev primers with pEGN-MOP-Vg9 as template using
Phusion polymerase. Such generated wild type TCR chains andmutant TCR chains were expressed in 53/4 hybridoma cells by retro-
viral transduction (Soneoka et al., 1995).
Soluble protein production
cDNA encoding wild type BTN2A1 (S27 to V142) or BTN2A2 IgV domains (S31 to V146), or BTN2A1 IgV incorporating the
described mutations, were generated as gblocks (Integrated DNA Technologies) including the sequence for a C-terminal 6x
Histidine tag and cloned into the pET23a expression vector (Novagen). Proteins were overexpressed, purified and refolded as
described (Willcox et al., 2019). BTN2A1 and BTN2A2 IgV domains were refolded by dilution in 100 mM Tris, 400 mM L-Arginine-
HCl, 2 mM EDTA, 6.8 mM cystamine, 2.7 mM cysteamine, 0.1 mM PMSF, pH 8, overnight at 4C. The refolding mixture was
concentrated and purified by size exclusion chromatography on a Superdex-200 column (GE Healthcare) pre-equilibrated with
20 mM Tris, 150 mM NaCl, pH 8, or 20 mM Na3PO4 pH 7.4 buffer, or PBS. BTN3A1 IgV was expressed, refolded, and purified as
described (Salim et al., 2017). Soluble gd TCRs were generated in Drosophila S2 cells and purified by nickel chromatography as pre-
viously described (Willcox et al., 2012). TCRs were then biotinylated via a C-terminal BirA tag.
Flow cytometry/TCR tetramer staining
Flow cytometry staining of the samples were performed with the below mentioned antibodies and samples were measured on
FACSCalibur or LSRII flow cytometer (BD). The expression of BTN3A1 and BTN2A1 were detected with anti-huBTN3 (CD277) clone
103.2 (gift from David Olive) and anti-huBTN2A1 clone 1C7D (MBL), followed by secondary antibody F(ab’) Donkey anti mouse
IgG (H+L) R-PE (Jackson Immunoresearch). mIgG1,k isotype clone p3.6.2.81 (eBiosciences) and mIgG2a,k isotype clone-eBM2a
(eBiosciences) were used a isotype controls and were detected by above mentioned secondary antibody. N-terminal HA-tagged
BTN2A1 or BTN2A2 were detected using anti-HA-FITC (Biolegend). PBMC expanded human Vg9Vd2 T cells were detected with
FITC- conjugated anti-human Vd2 (BD Biosciences). Biotinylated soluble Vg9Vd2 TCRs were tetramerized by the addition of Strep-
tavidin-PE conjugate (ThermoFisher Scientific) at room temperature, and 1-2mg of tetramer used to stain 105 cells at 4C.
Surface plasmon resonance
SPR was performed as previously described (Willcox et al., 1999) on a BIAcore3000 using streptavidin-coated CM5 chips and HBS-
EP buffer (GE Healthcare). Biotinylated Vg9 TCRs, and control Vg2, or Vg4 TCRs (2000-3000 RU), were captured on the Streptavidin
chip. Analyte concentrations ranged from 1-200 mM.
Immunoprecipitation, surface biotinylation, and crosslinking
293T cells in which the BTN2A1 and BTN2A2 loci have been functionally inactivated (293T BTN2/ cells), or CHO CD80+ cells, were
transduced to overexpress HA-tagged BTN2A1 or BTN2A2, or BTN3A1, as indicated. Cells were surface biotinylated using EZ-Link
Sulfo NHS-LC-biotin (ThermoFisher, 0.8mg/mL in PBS) for 30 min on ice, quenched with 20mM Tris pH 7.5 for 5 min, washed in TBS,
and lysed in lysis buffer containing 1%NP40 in 20mMTris pH 7.5, 150mMNaCl ± 10mM iodoacetamide (Sigma). HA-tagged BTN2A1
or BTN2A2was immunoprecipitated using anti-HA resin (BioLegend). Immunoprecipitations were washed in lysis buffer and eluted in
nonreducing (NR) or reducing (R) SDS sample buffer and boiled, or incubated at 37C for 5 min before separation on 4%–20% SDS-
PAGE gels (BioRad). Proteins were transferred to PVDF using the BioRad TransBlot Turbo system, blocked in 3% BSA, then incu-
bated with streptavidin-HRP (Thermo). To investigate potential association of BTN2A1 and BTN3A1 at the cell surface, CHO cells
overexpressing BTN2A1-HA, FLAG-BTN3A1, or both, were treated with the soluble, membrane-impermeable crosslinker
sulfo-EGS (ThermoFisher) at 0.5mM in PBS, at 4C for 2 h. Following this, the reaction was quenched by addition of Tris pH 7.5
to 20mM. Cells were washed in TBS and lysed in 1% NP40 lysis buffer. After centrifugation to remove insoluble material, immuno-
precipitationwas carried out using anti-HA resin or 20.1 antibody bound to protein ASepharose (GEHealthcare). Immunoprecipitates
were run on duplicate 4%–20% gels (BioRad) and blotted with anti-BTN2A1 or anti-FLAG antibodies.
I-TASSER modeling of BTN2A1 and BTN2A2 ectodomains
The ectodomain structures of BTN2A1 (residues Q29-A248) and BTN2A2 (residues Q33-M265), were generated using the I-TASSER
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through the Protein Data Bank (PDB) library by LOMETS2, an online meta- threading server system for template-based protein pre-
diction. Continuous fragments were excised from LOMETS2 alignments and structurally reassembled by replica-exchange Monte
Carlo simulations. The simulation trajectories were then grouped and used as the initial state for second round I-TASSER assembly
simulations. Finally, lowest energy structural models were identified and refined by fragment-guided molecular dynamic simulations
to improve hydrogen-bonding contacts and omit steric clashes. Models were ranked based on their I-TASSER confidence (C) score
(range 5 to +2 with a higher score correlating with a higher confidence model).
Modeling the BTN2A1-IgV/Vg9 complex
The BTN2A1-IgV/Vg9 complex wasmodeled with HADDOCK (van Zundert et al., 2016). BTN2A1 residues (R65, K79, R124, Y126 and
E135) were classified as active in Vg9 binding based upon the results of SPR binding experiments. ‘Passively involved’ residues were
selected automatically. Vg9 residues (R20, D72, E70 and E76) selected for use as ambiguous interaction restraints to drive the dock-
ing process with BTN2A1were predicted from an initial homologymodel (generated by superimposing BTN2A1-IgV and Vg9 onto the
previously published BTNL3-IgV/Vg4 complex model (Melandri et al., 2018).
Analysis of structural modeling and mutagenesis data
R65 (located in the IgV domain of BTN2A1) forms a salt bridge interaction with E76 (in the Vg9 TCR chain). This interaction is likely to
be abolished by introducing Ala at this position in BTN2A1 IgV domain (R65A), consistent with abrogation of binding by the R65A
mutant. The hydroxyl group of S72 (BTN2A1) is in close proximity to V58 (TCR). Juxtaposition of this polar residue (S72) with a
hydrophobic residue (V58) is likely to be energetically unfavorable for binding in this region. By substituting an Ala (ie a non-polar res-
idue) at this position, the S72A mutation is likely to introduce hydrophobic interactions with V58, consistent with enhanced binding
compared to wild-type (11-15mM (S72A) versus 50mM (Wild-type)).
K79A leads to reduced binding to TCR (100mM). K79 forms a salt bridge interaction with E76 (TCR). Change to Ala will result in loss
of this interaction consistent with a reduction in binding affinity. The fact that binding is not totally abolished suggests that this inter-
action is a not a major contributor to the binding energy. Note however that E76 also contacts R65 (see above).
R124A mutation in BTN2A1 abolishes binding to TCR. The HADDOCK model suggests that R124 forms a salt bridge interaction
with E70 (Vg9-IgV TCR) and a hydrogen bonding interaction with the hydroxyl group of T83. These interactions will be lost when intro-
ducing an Ala at this position.
Y126A abolishes binding to TCR. Y126 forms multiple hydrophobic stacking interactions with I74 (HV4 region of Vg9-IgV). In addi-
tion, the hydroxyl group of Y126 forms a hydrogen bonding interaction with T77. These will be lost upon alanine substitution.
Although Y133A is located at the interface with Vg9, it does not mediate interactions with Vg9 TCR residues and hence it is unsur-
prising that substitution to alanine does not affect binding affinity. E135 forms a salt bridge interaction with R20 (TCR). Substitution to
Ala will result in a loss of this interaction, and consistent with this, E135A mutation abolishes binding to the TCR.
NMR
HSQC experiments were performed at 298K on 600MHz Bruker Avance III spectrometer equipped with a 5 mm TCI cryogenically
cooled triple resonance probe. Spectra were acquired using 100 mM 1H-15N-labeled BTN3A1. Experiments were processed using
Topspin 3.2 (Bruker). All analysis was performed using CCPN Analysis (Vranken et al., 2005). For analysis of BTN3A1/BTN2A1 inter-
action, the final concentration of each protein was 100mM, and a threshold of 0.015 weighted average ppm difference was used as a
cut-off to identify chemical shift perturbations in BTN3A1 residues upon BTN2A1 addition.
Software
Structural figures were generated in PyMOL (version 2.0.7; Schrodinger, LLC). SPR data was analyzed in BIAevaluation (GE Health-
care) and Origin 2015 (OriginLab).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analyses
Stimulation data and transcript visualization in Figures 1 and S1A were calculated and depicted using GraphPad Prism. Differences
between transduced and untransduced cells were tested using 2-way ANOVA and unpaired multiple t test using the Holm-Sidak
method.
DATA AND CODE AVAILABILITY
The RNaseq data of radiation hybrid clones filtered for transcribed human genes are available at Mendeley data https://doi.org/10.
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